Del Poeta G, Stasi R, Venditti A, Cox C, Aronica G, Masi M, Bruno A, Simone M D, Buccisano F, Papa G
Department of Hematology, University Tor Vergata, Ospedale S. Eugenio, Rome, Italy.
Leuk Lymphoma. 1995 Mar;17(1-2):111-9. doi: 10.3109/10428199509051710.
The clinical significance of the expression of CD7 antigen on the blasts of 207 consecutive patients with de novo acute myeloid leukemia (AML) was evaluated. For this purpose, fifty-three CD7+ patients (23 females and 30 males; mean age 52 years) were analyzed and classified into the following subtypes according to French-American-British (FAB) classification: 7 M0, 13 M1, 9 M2, 1 M3, 9 M4, 14 M5. Immunophenotypic studies were carried out by flow cytometry and blast cells were selected on the basis of forward light scatter gating and pan-myeloid marker, either CD13 or CD33. All the CD7+ patients were negative for surface CD3 and T-cell-receptor (TCR) molecules. We found no correlation between CD7 expression and sex, age, hepatosplenomegaly and/or central nervous system involvement. The immaturity of CD7+ leukemic cells was supported by the high expression of CD34 (P = 0.001). CD7 positivity was significantly associated with a white blood cell count (WBC) greater than 100 x 10(9)/L (P = 0.003). P-Glycoprotein (P-170) expression was also evaluated in 135 patients by a flow-cytometric assay: there was a close relationship between CD7 and P-170 positivity (P < 0.001). For remission induction, all patients received therapeutic regimens routinely used for AML. The complete remission (CR) rate was significantly lower in CD7+ cases (32% vs 74%, P = 0.001). The overall survival and disease free survival rate of CD7+ AML was lower than those of CD7- patients (P < 0.001 and = 0.002, respectively). CD7+ AML with coexpression of CD14 had a particularly unfavourable response and prognosis in comparison with CD7+ patients without CD14.(ABSTRACT TRUNCATED AT 250 WORDS)
对207例初发急性髓系白血病（AML）患者原始细胞上CD7抗原表达的临床意义进行了评估。为此，分析了53例CD7阳性患者（23例女性和30例男性；平均年龄52岁），并根据法美英（FAB）分类法将其分为以下亚型：7例M0，13例M1，9例M2，1例M3，9例M4，14例M5。通过流式细胞术进行免疫表型研究，并根据前向光散射门控和全髓系标志物（CD13或CD33）选择原始细胞。所有CD7阳性患者的表面CD3和T细胞受体（TCR）分子均为阴性。我们发现CD7表达与性别、年龄、肝脾肿大和/或中枢神经系统受累之间无相关性。CD34的高表达支持了CD7阳性白血病细胞的不成熟性（P = 0.001）。CD7阳性与白细胞计数（WBC）大于100×10⁹/L显著相关（P = 0.003）。还通过流式细胞术检测对135例患者的P-糖蛋白（P-170）表达进行了评估：CD7与P-170阳性之间存在密切关系（P < 0.001）。对于缓解诱导，所有患者均接受常用于AML的治疗方案。CD7阳性病例的完全缓解（CR）率显著较低（32%对74%，P = 0.001）。CD7阳性AML的总生存率和无病生存率低于CD7阴性患者（分别为P < 0.001和 = 0.002）。与无CD14的CD7阳性患者相比，共表达CD14的CD7阳性AML反应和预后特别差。（摘要截短于250字）
